ZA200409445B - MUC-1 antigen with reduced numbr of VNTR repeat units. - Google Patents

MUC-1 antigen with reduced numbr of VNTR repeat units.

Info

Publication number
ZA200409445B
ZA200409445B ZA200409445A ZA200409445A ZA200409445B ZA 200409445 B ZA200409445 B ZA 200409445B ZA 200409445 A ZA200409445 A ZA 200409445A ZA 200409445 A ZA200409445 A ZA 200409445A ZA 200409445 B ZA200409445 B ZA 200409445B
Authority
ZA
South Africa
Prior art keywords
numbr
muc
antigen
reduced
repeat units
Prior art date
Application number
ZA200409445A
Other languages
English (en)
Inventor
Neil Burden
Paul A Hamblin
Jonathan Henry Ellis
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ZA200409445B publication Critical patent/ZA200409445B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200409445A 2002-05-24 2004-11-23 MUC-1 antigen with reduced numbr of VNTR repeat units. ZA200409445B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0212046.7A GB0212046D0 (en) 2002-05-24 2002-05-24 Vaccines

Publications (1)

Publication Number Publication Date
ZA200409445B true ZA200409445B (en) 2006-02-22

Family

ID=9937394

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200409445A ZA200409445B (en) 2002-05-24 2004-11-23 MUC-1 antigen with reduced numbr of VNTR repeat units.

Country Status (20)

Country Link
US (1) US20060251665A1 (enExample)
EP (1) EP1527177A2 (enExample)
JP (1) JP2005526520A (enExample)
KR (1) KR20050004211A (enExample)
CN (1) CN100408682C (enExample)
AR (1) AR039846A1 (enExample)
AU (1) AU2003240729B2 (enExample)
BR (1) BR0311211A (enExample)
CA (1) CA2485816A1 (enExample)
GB (1) GB0212046D0 (enExample)
IL (1) IL165156A0 (enExample)
IS (1) IS7526A (enExample)
MX (1) MXPA04011527A (enExample)
NO (1) NO20044947L (enExample)
NZ (1) NZ536668A (enExample)
PL (1) PL374569A1 (enExample)
RU (1) RU2303069C2 (enExample)
TW (1) TW200407426A (enExample)
WO (1) WO2003100060A2 (enExample)
ZA (1) ZA200409445B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
ES2476990T3 (es) 2003-11-12 2014-07-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sistema para tratar y prevenir cáncer de mama
WO2005046622A2 (en) 2003-11-12 2005-05-26 Therion Biologics Corporation Custom vectors for treating and preventing pancreatic cancer
EP1848804B1 (en) * 2005-01-28 2011-10-05 Ramot at Tel Aviv University, Ltd. Anti-muc1 alpha beta antibodies
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
WO2011156751A2 (en) * 2010-06-11 2011-12-15 University Of Georgia Research Foundation, Inc. Immunogenic vaccine
CN106215179A (zh) * 2010-06-11 2016-12-14 乔治亚大学研究基金公司 免疫原性疫苗
JP2014518841A (ja) * 2011-02-24 2014-08-07 オンコシレオン インク． アジュバントを備えたｍｕｃ１ベースのグリコリポペプチドワクチン
CA2954892A1 (en) * 2016-01-19 2017-07-19 Pfizer Inc. Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens
AU2017336269B2 (en) * 2016-09-28 2022-06-16 Bavarian Nordic A/S Compositions and methods for enhancing the stability of transgenes in poxviruses
EP3794042B1 (en) 2018-05-18 2024-03-27 Daiichi Sankyo Co., Ltd. Anti-muc1- exatecan antibody-drug conjugate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101028523A (zh) * 1995-11-30 2007-09-05 德克萨斯州立大学董事会 诊断和治疗肿瘤的方法及组合物
CA2282300C (en) * 1997-02-24 2011-08-02 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
US6228843B1 (en) * 1999-04-23 2001-05-08 University Technology Corporation Method of using PKC inhibiting compounds to treat vascular disease
WO2001018035A2 (en) * 1999-09-08 2001-03-15 Transgene S.A. Muc-1 derived peptides
GB9930359D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
WO2001057068A1 (en) * 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy
US20020142047A1 (en) * 2001-01-19 2002-10-03 Johnson Mark E. Microsphere delivery of mucin peptides
US7125663B2 (en) * 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
EP1572918B1 (en) * 2002-04-15 2011-10-19 Oncothyreon Inc. Synthetic glyco-lipo-peptides as vaccines
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines

Also Published As

Publication number Publication date
JP2005526520A (ja) 2005-09-08
AU2003240729B2 (en) 2007-12-20
TW200407426A (en) 2004-05-16
KR20050004211A (ko) 2005-01-12
CA2485816A1 (en) 2003-12-04
MXPA04011527A (es) 2005-09-30
NO20044947L (no) 2005-12-16
RU2303069C2 (ru) 2007-07-20
CN1668746A (zh) 2005-09-14
WO2003100060A3 (en) 2004-02-19
BR0311211A (pt) 2005-03-01
AU2003240729A1 (en) 2003-12-12
PL374569A1 (en) 2005-10-31
IL165156A0 (en) 2005-12-18
GB0212046D0 (en) 2002-07-03
NZ536668A (en) 2007-01-26
IS7526A (is) 2004-11-11
CN100408682C (zh) 2008-08-06
NO20044947D0 (no) 2004-11-12
WO2003100060A2 (en) 2003-12-04
RU2004134331A (ru) 2005-08-27
AR039846A1 (es) 2005-03-02
EP1527177A2 (en) 2005-05-04
US20060251665A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
EP1572131A4 (en) ANTIBODY THERAPY
EP1494693A4 (en) SPECIFIC ANTIBODIES TO CRIPTO
PL375405A1 (en) Antibodies
IL202682A0 (en) Interleukin-10 antibodies
AU2003217912A8 (en) Antibody optimization
PT1599504E (pt) Anticorpo modificado
IL175710A0 (en) Anti-mpl antibody
GB0206360D0 (en) Viral antigens
GB0206359D0 (en) Viral antigens
EP1566367A4 (en) LUMINESCENT GLASS
NO20044947D0 (no) MUC-1 antigen med redusert antall VNTR gjentagene enheter
AU2003278466A1 (en) Transportation payment
GB0306618D0 (en) Antibody
GB0226878D0 (en) Antibodies
AU2003232550A1 (en) Two dimensional identification code structure
GB0219534D0 (en) Glass advertising
AU2003271093A1 (en) Antigen recognizing antibody
AU2003237701A1 (en) Vaccines
HK1077600A (en) Muc-1 antigen with reduced number of vntr repeat units
AU2003295590A1 (en) Translucent card
GB0217143D0 (en) Getter
GB0217742D0 (en) Novel antibodies
GB0218235D0 (en) Antibodies
GB0218234D0 (en) Antibodies
GB0218229D0 (en) Antibodies